Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

66 results about "Retinal tissue" patented technology

The retina is a thin layer of tissue that lines the back of the eye on the inside. It is located near the optic nerve. The purpose of the retina is to receive light that the lens has focused, convert the light into neural signals, and send these signals on to the brain for visual recognition.

Construction and application of a modified AAV-8 serotype targeting various retinal layers

The present invention belongs to the field of genetic engineering and biotechnology, and relates to the screening, construction and application of a modified type of AAV-8 serotype for gene targeting and expression. The modified type of the AAV-8 serotype of the present invention inserts 10 amino acid sequences between the 590th amino acid and the 591st amino acid of the AAV-8 serotype capsid protein sequence as shown in SEQ ID NO.2, wherein the 3rd to 9th amino acids are amino acid sequences obtained by screening. The modified serotype of the present invention targets each layer of the retina, and the fluorescence effect after infection is stronger, and it can be clearly and intuitively observed that the exogenous gene can be efficiently expressed in each layer of the retina of the targeted tissue, including the retinal ganglion cell layer, the inner nuclear layer, the outer nuclear layer, the photoreceptor cell layer and the retinal pigment epithelial cell layer, and has better and more targeted tissue expression than the wild-type serotype when the same amount of virus is used.
Owner:SHANGHAI OPHTHAL-BRIGHT BIOMEDICINE TECH

Human cell population comprising human retinal progenitor cells without an ISL1 gene for transplantation and methods of use thereof

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.
Owner:RACTHERA CO LTD +1

Method for preventing melatonin from falling off

The method comprises the following steps: fixing with a pre-fixing solution, wrapping and forming with a solid agent, fixing with a fixing solution, embedding with an embedding agent, decomposing melanin with a melanin decomposing solution, pre-decoloring with a pre-decoloring solution, decoloring with a decoloring solution, and eluting with a rinsing solution. The invention provides a melanin removing method capable of effectively avoiding retina RPE layer cell exfoliation, protein denaturation and nucleic acid degradation. The method mainly comprises the following steps: keeping the original state of tissue cells by adopting a pre-fixing solution, keeping the complete tissue structure by adopting a solid agent, decomposing melanin particles by adopting a melanin decomposing solution composed of various extracts, separating melanin by adopting a pre-decoloring solution and a decoloring solution, eluting the melanin decomposed on the surface of the tissue by adopting a rinsing solution, and the like. On the premise that the retina tissue structure is intact and protein, nucleic acid and cell structures on the surface of the tissue section are not damaged, melanin particles in the tissue section are effectively decomposed, the biological activity of various organelles on the surface of the section is kept, and the requirements of subsequent chemical staining of various tissues are met.
Owner:BEIJING EPSILON BIOTECHNOLOGY CO LTD

Method for producing retinal tissue and retina-related cells

ActiveUS12378520B2Senses disorderCulture processRetinal progenitorSuspension culture
The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
Owner:SUMITOMO CHEM CO LTD +1

Production method for retinal tissue

The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3):(1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state,(2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.
Owner:RACTHERA CO LTD +1

Phase-based optoretinography using tissue velocity

PendingUS20250143566A1Medical automated diagnosisEye diagnosticsNuclear medicineRetinal dysfunction
Phase-based optoretinography (ORG) is performed using tissue velocity obtained from a modified optical coherence tomography (OCT) system. A swept-source generated OCT A-scan is used to assemble a 2-dimensional profile of the retinal tissue (B-scan) by laterally scanning the imaging beam. These B-scans can be taken at multiple time-points and assembled into a M-scan, which displays motion of a particular cross-section of retinal tissue (after correction for bulk motion). The method captures the changes between each timestep of the M-scan to deduce tissue velocities of the COST, ROST, and IS / OS, among others. An initial contraction of outer segments is detected in outer segments, followed by an elongation shortly thereafter. The tissue velocity measurements can be used to infer retinal dysfunction without the need for costly and computationally expensive scans using adaptive optics.
Owner:RGT UNIV OF CALIFORNIA

Application of asarone in preparation of medicine for treating and / or preventing eye diseases, composition and application of composition

The invention provides application of asarone in preparation of a medicine for treating and / or preventing eye diseases, a composition and application of the composition, and belongs to the technical field of biological medicine. The asarone composition comprises the following components: asarone, soybean oil, egg yolk lecithin, glycerol, sodium hydroxide and water, wherein the asarone comprises at least one of alpha-asarone, beta-asarone and gamma-asarone. The asarone or the asarone composition disclosed by the invention is administered in modes of eye drop, oral administration, injection and the like, can effectively reduce intraocular pressure, protect retinal ganglion cells, improve retinal functions, reduce vascular leakage caused by neovascularization age-related macular degeneration, can reduce the MDA content in retina tissues of optic neuritis and cataract, and can be used for preventing and treating the optic neuritis and the cataract. The apoptosis of retinal cells in diabetic retinopathy is reduced, and the tear secretion amount of a rat with xerophthalmia is increased. The invention provides an effective prevention and treatment basis for asarone in the aspect of treating and / or preventing the eye diseases.
Owner:CHENGDU XINRUI ZHIYUAN BIOPHARMACEUTICAL CO LTD

A novel structural polysaccharide derived from the roots of *Trifolium repens* and its combination with vitamin E and its applications.

This invention discloses a novel structural polysaccharide SYQE3-F derived from the roots of *Tripterygium wilfordii*, its preparation method, pharmaceutical composition, and applications, belonging to the field of biomedical technology. This invention is the first to isolate and purify a homogeneous polysaccharide SYQE3-F from the roots of *Tripterygium wilfordii*, with an average molecular weight of 13.174 kDa. Its main chain consists of →4)-β-D-GlcpA-(1→) and →2)-α-D-Manp-(1→), and its side chains include t-Galp and t-Araf. This invention also discloses a pharmaceutical composition containing this polysaccharide and vitamin E. In vitro and in vivo experiments show that this polysaccharide can effectively break down choroidal occlusion barriers and significantly promote the transport of vitamin E to the target retinal tissue, providing a novel natural drug combination for the clinical treatment of DR.
Owner:ZHEJIANG PROVINCIAL LITONGDE HOSPITAL (ZHEJIANG PROVINCIAL INST OF MENTAL HEALTH)

Methods and systems for large spot retinal laser treatment

In some embodiments, a system for providing a therapeutic treatment to a patient's eye includes a treatment beam source configured to transmit a treatment beam along a treatment beam path. The system further includes a processor coupled to the treatment beam source, the processor being configured to direct the treatment beam onto retinal tissue of the patient's eye and deliver a series of short duration pulses from the treatment beam onto the retinal tissue at a first treatment spot to treat the retinal tissue. In some embodiments, a pre-treatment evaluation method using electroretinography (ERG) data may be used to predict effects of treatment beams at different power values and to determine optimal power values.
Owner:IRIDEX CORP

New Application of ALW-II-41-27 in the Treatment of Ophthalmic Diseases

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV

Auxiliary device for taking out eyeball retina specimen of laboratory mouse

The utility model aims to provide an auxiliary device for taking out an eyeball retina specimen of an experimental mouse, which relates to the technical field of medical instruments and is characterized in that during use, a cornea of a taken-down eyeball of the mouse is placed below an operating cylinder upwards, and an arc-shaped sheet is controlled to clamp the cornea by rotating a cover plate of a reducing mechanism; mouse eyeballs of different sizes can be fixed through the diameter changing mechanism, in the moving process, the arc-shaped piece abuts against the blade to move towards the circle center of the base to be attached to the cornea, the mounting ring is rotated to cut the cornea, then the clamping mechanism slides downwards to be close to and clamp the cornea and the crystalline lens, and the cornea and the crystalline lens are separated. Then, the optic cup-shaped tissue with the cornea and the crystalline lens removed is reversed, the clamping rod continues to be used for fixing the optic nerve, the cup opening of the optic cup-shaped tissue abuts against the arc-shaped piece, then the clamping rod translates downwards, and the internal retina tissue is completely extruded out of the optic cup-shaped tissue through the innate subretinal space; therefore, an eyeball retina specimen is obtained.
Owner:THE 900TH HOSPITAL OF THE CHINESE PEOPLES LIBERATION ARMY JOINT LOGISTICS SUPPORT FORCE

Method and system for disease analysis and interpretation

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.
Owner:VOXELERON INC

Novel AAV capsid-modified strain and use thereof

PCT designated stage expiredWO2023207792A9Senses disorderVirus peptidesTropismImmunogenicity
Provided are a method for modifying an rAAV vector to improve the retinal tissue tropism, and infection and expression ability thereof and reduce the immunogenicity thereof, a vector obtained by means of the method, and use thereof.
Owner:SHANGHAI LANGSHENG BIOTECHNOLOGY CO LTD

Method for producing retinal tissue and retina-related cells

PendingUS20250354112A1Senses disorderCulture processRetinal progenitorProgenitor cell
The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
Owner:SUMITOMO CHEM CO LTD +1

Capsid rearrangement adeno-associated virus vectors and uses thereof

ActiveCN119350454ASenses disorderVirus peptidesDiseaseReassortant Viruses
The invention provides a capsid rearrangement adeno-associated virus vector and application thereof. In particular, the present invention provides a capsid rearrangement serotype based on an existing AAV. The rearrangement serotype provided by the invention has higher toxin production, high real heart rate and low immunogenicity, and has high transduction activity in human retina tissues. The invention also provides a recombinant virus vector containing the rearranged AAV capsid and application of the recombinant virus vector in disease treatment.
Owner:SHANGHAI LANGSHENG BIOTECHNOLOGY CO LTD

Methods and devices for measuring structural and functional properties of tissue

Provided herein are methods and systems for determining a parameter across a surface of a tissue such as a retinal tissue of an eye of a subject. In some cases, the determined parameter is tissue oxygenation which can be used for a variety of clinical applications such as diagnosing and / or modeling a disease in the subject. In some examples, the method is performed by detecting one or more optical signals from the tissue using an optical detector, and processing the detected optical signals to characterize and map the parameter across the surface of the tissue. The methods and systems provided herein can prove accurate physics-based models of parameters such as tissue oxygenation across a heterogeneous tissue surface.
Owner:BIOXYTECH RETINA INC

Engineered reprogramming factors and uses thereof for treating eye diseases

PCT designated stage expiredWO2025002450A1Organic active ingredientsVirusesRejuvenationRetinal regeneration
The present application provides methods of rejuvenating a population of cells (e.g., retinal cells) of an eye, comprising introducing into the population of cells (e.g., retinal cells), or to the eye, an effective amount of an engineered reprogramming factor that is deficient in liquid-liquid phase separation (LLPS). Also provided are methods of delaying or preventing the progression of aging of a retinal tissue, or vision impairment or loss, in an individual (e.g., human), methods of preserving or improving the viability and / or function of an retinal ganglion cell (RGC), methods of preserving or improving vision, methods of promoting retinal regeneration, and methods of treating and / or preventing aging, damage, or disease or condition in a retinal tissue, or vision impairment or loss, in an individual, using any of the rejuvenation methods and / or LLPS-deficient engineered reprogramming factors described herein.
Owner:SHENZHEN GENTURN LIFE CO LTD

Methods and apparatus for imaging, analysing images and classifying presumed protein deposits in the retina

The present disclosure provides methods and an apparatus for imaging and analysing images of presumed protein deposits in the retina, retinal tissue or retinal structures and discloses methods differentiating or classifying these deposits and other optical signals from retinal structures into 1) whether they contain or do not contain classes, of proteins or protein deposits called amyloids or other proteins and / or protein deposits related to neurodegenerative eye and brain disease(s): 2) which type(s) of amyloid or other proteins or protein deposits they contain, as well as 3) whether the form and / or properties of the deposit are associated with a class of diseases or with one or another specific condition(s) (or disease(s)); whether or not this is a disease or class of disease associated with the retina or more generally with the nervous system, including the brain or 4) classified as associated with one or another level of severity of condition(s), or disease(s).
Owner:CAMPBELL MELANIE CROMBIE WILLIAMS +2

A method for preventing the exfoliation of melanin

A method for preventing the retinal pigment from being removed from the network, comprising the steps of pre-fixing liquid fixation, solidifying agent wrapping shaping, fixing liquid fixation, embedding agent embedding, melanin decomposition liquid decomposing melanin, pre-decoloring liquid pre-decoloring, decoloring liquid decoloring and rinsing liquid elution. A method for removing melanin is provided to effectively avoid the retinal RPE layer cell from being removed from the network, protein denaturation and nucleic acid degradation. The method mainly adopts the following steps: pre-fixing liquid to maintain the original state of tissue cells, solidifying agent to maintain the integrity of tissue structure, melanin decomposition liquid composed of various extracts to decompose melanin particles, pre-decoloring liquid and decoloring liquid to separate melanin, and rinsing liquid to elute the decomposed melanin on the surface of the tissue, etc. Under the premise of ensuring the integrity of the retinal tissue structure, not damaging the surface protein, nucleic acid and cell structure of the tissue section, effectively decomposing the melanin particles in the tissue section, maintaining the biological activity of various organelles on the section surface and meeting the needs of subsequent various histochemical staining.
Owner:BEIJING EPSILON BIOTECHNOLOGY CO LTD

Method for maturation of retinal tissue containing continuous epithelium

ActiveUS12534706B2Culture processNervous system cellsEpitheliumRetinal progenitor
The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.
Owner:RACTHERA CO LTD +1

Methods, devices, electronic devices and readable storage media for identifying fundus lesions

A method and apparatus for identifying fundus lesions are provided. The method includes: acquiring OCT fundus images of a specific patient; using a first neural network model to determine the boundary information of retinal tissue in the OCT fundus images, and segmenting the OCT fundus images into multiple image blocks based on the boundary information of the retinal tissue; providing the multiple image blocks to a second neural network model to obtain the fundus lesion type of the specific patient; the second neural network model calculating the feature vector of each image block and the attention weight of each image block for the specified fundus lesion type, and obtaining the fused feature vector through weighted calculation to obtain the identification result for the specified fundus lesion type. The second neural network model combines spatial saliency and scanning position saliency to enhance important information in the image block group and filter out unimportant information, thereby achieving low-cost model training and application.
Owner:ALIBABA (CHINA) CO LTD

Construction method of Rpgr gene knockout mouse model

The invention discloses a construction method of an Rpgr gene knockout mouse model, and belongs to the technical field of gene engineering. The construction method comprises the following steps: injecting the recombinant gRNA expression vector provided by the invention into a CRISPR / Cas9 transgenic mouse body through subretinal injection, and obtaining an Rpgr gene knockout mouse model by utilizing a CRISPR / Cas9 gene editing technology; the mouse is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 transgenic Or injecting the recombinant gRNA expression vector provided by the invention and an expression vector containing a nucleotide sequence for expressing Cas9 into a wild type mouse body, and obtaining the Rpgr gene knockout mouse model by utilizing a CRISPR / Cas9 gene editing technology. The construction method provided by the invention is good in knockout effect, low in cost, high in efficiency, good in durability after knockout, complete in retina tissue structure, less in time consumption, simple in method and high in flexibility, large-batch screening is not needed, damage of whole-body knockout to other organ functions of mice is avoided, the research time is greatly saved, and the research efficiency is improved.
Owner:WUHAN JUNXI BIOTECHNOLOGY CO LTD

Application of Reelin protein in preparation of medicine for treating retinal injury

ActiveCN119033914AImprove abnormal morphologycause deathSenses disorderPeptide/protein ingredientsOptic nerveRetinal dysfunction
The invention provides an application of Reelin protein in preparation of a medicine for treating retinal injury, relates to the technical field of protein medicines, and applies the Reelin protein in preparation of the medicine for treating the retinal injury. The retinal ischemia-reperfusion injury process is adjusted by improving retinal tissue morphological abnormality after the retinal injury, retinal optic nerve cell death after the retinal injury, retinal dysfunction after the retinal injury and retinal cell apoptosis after the retinal injury. When the Reelin protein is used for preparing the medicine for treating the retinal injury, a basis can be provided for a novel medicine for treating the retinal ischemia-reperfusion injury.
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Method for determining normal retinal tissue region in cell aggregate, and method for producing retinal tissue implantable in animals

PCT designated stageWO2025164733A1Senses disorderImage analysisCellPathology
Provided is a method for quickly, objectively and properly evaluating the quality of a cell aggregate by determining the quality of the cell aggregate by determining an evaluation score on the basis of a determination criterion from an appropriate point of view with respect to an image of the cell aggregate. With respect to a cell aggregate which can include a retinal tissue derived from a pluripotent stem cell, in an image region of the cell aggregate which is each of an inverted observation image of the cell aggregate and an elected observation image of the cell aggregate, a region that is determined as satisfying a color-related candidate region determination criterion for each of the inverted observation image and the elected observation image on the basis of the candidate region determination criterion is identified as a candidate region included in a region that is a candidate for a normal retinal tissue region. Subsequently, in the candidate region of each of the inverted observation image and the elected observation image, a candidate region that is determined as satisfying a brightness- and / or shape-related normal region determination criterion for each of the inverted observation image and the elected observation image is determined as the normal retinal tissue region.
Owner:RACTHERA CO LTD

Method for producing retinal tissue

The present disclosure includes: a method for producing a retinal tissue, the method comprising: (1) inoculating pluripotent stem cells to an area A having cell adhesion on a culture substrate at a density of 0.5 * 105 cells / cm < 2 > to 2.5 * 105 cells / cm < 2 >, (2) culturing the pluripotent stem cells inoculated in step (1) in a culture medium containing a ROCK inhibitor for 1-16 hours, and (3) culturing the pluripotent stem cells inoculated in step (1) in a culture medium containing a ROCK inhibitor for 1-16 hours, and (3) culturing the cells obtained after step (2) in a culture medium comprising a BMP signaling activator; a retinal tissue produced by the method; a composition comprising the retinal tissue; and the like.
Owner:RICK SHENGLE CO LTD +1

Resin chip for tissue implantation, tissue implantation device, retinal tissue implantation method and retinal tissue implantation kit

A tissue transplantation resin tip and the like that allow easy transplantation of a tissue sucked inside are provided. A tissue transplantation resin tip 10 according to the present invention includes a needle tube 1 that can be inserted into an eyeball. The needle tube includes a main body portion 11 that extends linearly, and a front end portion 12 that is bent with respect to the main body portion and extends linearly, and that discharges a tissue T from a front end 121. A length L1 of the needle tube is 25 mm or more and 50 mm or less, a cross-sectional external shape of the front end portion has an oval shape having a major axis D1 of 0.8 mm or more and 1.5 mm or less, and a minor axis D2 of 0.5 mm or more and 1.0 mm or less, the front end of the front end portion is a bevel surface that extends in a direction substantially perpendicular to the main body portion, and that has a bevel angle Θ1 of 50° or more and 85° or less, the hardness of the front end portion is 0.15 N or more and 0.30 N or less, and the hardness of the center of the needle tube is 0.80 N or more and 1.50 N or less.
Owner:RIKEN CO LTD +1

Retinal organ culture medium and application thereof

The invention discloses a retinal organoid culture medium and application thereof, and relates to the field of organoid culture. The culture medium comprises a basic culture medium and specific addition factors, wherein the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein, and the specific addition factors comprise A8301, Forskolin, Prostaglandin E2, R-Spondin protein, Noggin protein and FGF10 (Fibroblast Growth Factor 10) protein. The culture medium disclosed by the invention can be used for obtaining retina organoid culture from retina tissue culture, and is high in organoid formation rate, high in biological consistency, high in research value and wide in application prospect.
Owner:BOZHEN BIOTECHNOLOGY (HANGZHOU) CO LTD

A special retinal cryo-peeling stage and experimental equipment

The utility model provides a kind of special stage of retinal low temperature stripping and experimental equipment, it is related to experimental apparatus field. Including stage body, the top of stage body is horizontal plane, and recess is set in its top;Ice water channel is set below recess, and ice water channel is through stage body. By setting the stage body of top surface level, and setting recess to place retina tissue, so that the stripping operation of retina can be stably carried out, and tissue is not easy to shift;Ice water channel is set for the flow of ice water mixture, keep the low temperature of stage body, since it is just below recess, and then cold quantity can be transmitted to recess faster, ice water mixture is directly replenished to keep low temperature continuously, and PBS solution is not needed to be pre-cooled frequently, so that liquid exchange is convenient and fast;Stage body can also support operator's both hands, improve operation stability.
Owner:CIXI PEOPLES HOSPITAL MEDICAL HEALTH GRP (CIXI PEOPLES HOSPITAL)

Method and system for disease analysis and interpretation

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.
Owner:VOXELERON INC